As an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.
mechanism of action
Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.